Published in Blood Weekly, October 30th, 2003
"The support from the Department of Defense allows us to make development of our unique anthrax drug, ETI-205, a top priority," said Stephen Sudovar, president and CEO of Elusys. "This funding enables us to complete the last phases of our efficacy studies and to scale up production in preparation for human safety studies."
Elusys is developing a heteropolymer (HP) drug to remove anthrax toxin from the bloodstream. "The toxin is the component of anthrax that can...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.